General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Steady Dividend Plays: 3 Stocks Promising Reliable Payouts in 2024 | investorplace.com • |
Here's why you should buy these 3 stocks and hold them forever | finbold.com • |
Here's why you should buy these 3 stocks and hold them forever- Finance in Bold | news.google.com • |
Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald | news.google.com • |
Investing in Johnson & Johnson (NYSE:JNJ) five years ago would have delivered you a 46% gain | news.google.com • |
(JNJ) Investment Report | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-16 | 2024-03 | 2.64 | 2.71 | 0.07 | 2.65% |
2024-01-23 | 2023-12 | 2.27 | 2.29 | 0.02 | 0.88% |
2023-10-17 | 2023-09 | 2.52 | 2.66 | 0.14 | 5.56% |
2023-07-20 | 2023-06 | 2.61 | 2.8 | 0.19 | 7.28% |
2023-04-18 | 2023-03 | 2.51 | 2.68 | 0.17 | 6.77% |
2023-01-24 | 2022-12 | 2.22 | 2.35 | 0.13 | 5.86% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-17 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-17 | Raymond James | Upgrade | Outperform | Outperform |
2023-10-17 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-11 | Barclays | Upgrade | Equal-Weight | Equal-Weight |
2023-10-10 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-10 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-12 | BROADHURST VANESSA | Officer | 15.04K | Sale |
2024-02-12 | DECKER ROBERT J | Officer | 19.70K | Conversion of Exercise of derivative security |
2024-02-12 | DUATO JOAQUIN BOIX | Chief Executive Officer | 364.19K | Conversion of Exercise of derivative security |
2024-02-12 | FASOLO PETER M | Officer | 112.08K | Conversion of Exercise of derivative security |
2024-02-12 | HAIT WILLIAM | Officer | 38.65K | Conversion of Exercise of derivative security |
2024-04-30 | REED JOHN C | Officer | 11.58K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 247.48M | 40.96B | 9.52% |
2023-06-29 | Blackrock Inc. | 199.34M | 33.00B | 7.67% |
2023-06-29 | State Street Corporation | 141.83M | 23.48B | 5.46% |
2023-06-29 | Geode Capital Management, LLC | 49.70M | 8.23B | 1.91% |
2023-06-29 | Morgan Stanley | 41.67M | 6.90B | 1.60% |
2023-06-29 | JP Morgan Chase & Company | 31.78M | 5.26B | 1.22% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 81.05M | 13.42B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 61.87M | 10.24B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 29.26M | 4.54B | 1.13% |
2023-08-30 | SPDR S&P 500 ETF Trust | 26.52M | 4.29B | 1.02% |
2023-06-29 | Vanguard Index-Value Index Fund | 22.57M | 3.74B | 0.87% |
2023-08-30 | iShares Core S&P 500 ETF | 22.52M | 3.64B | 0.87% |
Dividend | Date |
---|---|
1.24 | 2024-05-20 |
1.19 | 2024-02-16 |
1.19 | 2023-11-20 |
1.19 | 2023-08-25 |
1.19 | 2023-05-22 |
1.13 | 2023-02-17 |
Split | Date |
---|---|
2 : 1 | 2001-06-13 |
2 : 1 | 1996-06-12 |
2 : 1 | 1992-06-10 |
2 : 1 | 1989-05-11 |
3 : 1 | 1981-05-19 |
3 : 1 | 1970-05-18 |
Was bagholding in the trade window. Hoping for a breakout $JNJ also a safe reopening play
u think i can play $JNJ for reopening? Bought it cuz it doesnt budge. Can sleep at night
Ooh weakness. Premarket about to wreck my entry. $JNJ
Futures coming down due to bad ER’s this morning
$JNJ May come to $146 due to bad news and lower futures, be very cautious and buy at dips
$CNBC covering $JNJ
Bullish, temporary wait will lead the way higher
$JNJ time to pickup the price, gonna run to $157+ now
Agreed Matt. That’s what company has stated as well which I pasted below an hour back,
So nothing to worry buy dips and results going to be good
Temporary news to create panic right before ER morning
Don’t be in the trap. $JNJ has dozens of great successful products, Fundamentally it’s very strong.
So don’t panic sell, downside is very restricted and limited here. It’s going to go bullishly up, buy any dip buy don’t be in trap right before ER, results going to be amazing.
Johnson & Johnson stated that the participant's illness is reviewed and evaluated by an independent data and safety monitoring board, as well as by the company's clinical and safety physicians. The company said that such temporary prohibitions continue in large trials, in which more than 10 thousand people are tried.
Johnson & Johnson said that this study has been banned. There is no point in stopping the trial on behalf of the Medical Regulatory Board
$JNJ just a planned news right before ER so don’t panic and enjoy, everything going to be ok
Temporary news to create panic right before ER morning
Don’t be in the trap. $JNJ has dozens of great successful products, Fundamentally it’s very strong.
So don’t panic sell, downside is very restricted and limited here. It’s going to go bullishly up, buy any dip buy don’t be in trap right before ER, results going to be amazing.